Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

被引:231
作者
Bretzel, Reinhard G. [1 ]
Nuber, Ulrike [1 ]
Landgraf, Wolfgang [2 ]
Owens, David R. [3 ]
Bradley, Clare [4 ]
Linn, Thomas [1 ]
机构
[1] Univ Giessen, Med Klin & Poliklin 3, D-35392 Giessen, Germany
[2] Sanofi Aventis Deutschland GmbH, Med Affairs, Berlin, Germany
[3] Llandough Univ Hosp, Diabet Res Unit, Cardiff, Wales
[4] Univ London Royal Holloway & Bedford New Coll, Surrey, England
关键词
D O I
10.1016/S0140-6736(08)60485-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background As type 2 diabetes mellitus progresses, oral hypoglycaemic agents often fail to maintain blood glucose control and insulin is needed. We investigated whether the addition of once-daily insulin glargine is non-inferior to three-times daily prandial insulin lispro in overall glycaemic control in adults with inadequately controlled type 2 diabetes mellitus taking oral hypoglycaemic agents. Methods In the 44-week, parallel, open study that was undertaken in 69 study sites across Europe and Australia, 418 patients with type 2 diabetes mellitus that was inadequately controlled by oral hypoglycaemic agents were randomly assigned to either insulin glargine taken once daily at the same time every day or to insulin lispro administered three times per day. The primary objective was to compare the change in haemoglobin A(1c) from baseline to endpoint (week 44) between the two regimens. Randomisation was done with a central randomisation service. Analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00311818. Findings 205 patients were randomly assigned to insulin glargine and 210 to insulin lispro. Mean haemoglobin A(1c) decrease in the insulin glargine group was -1 . 7% (from 8.7% [SD 1 . 0] to 7.0% [0.71]) and -1 . 9% in the insulin lispro group (from 8.7% [1.0] to 6.8% [0.9]), which was within the predefined limit of 0.4% for non-inferiority (difference=0.157; 95% Cl -0.008 to 0.322).106 (57%) patients reached haemoglobin A(1c) of 7% or less in the glargine group and 131 (69%) in the lispro group. In the glargine group, the fall in mean fasting blood glucose (-4.3 [SD 2.3] mmol/L vs -1 . 8 [2.3] mmol/L; p<0 . 0001) and nocturnal blood glucose (-3.3 [2.8] mmol/L vs -2.6 [2.9] mmol/L; p=0.0041) was better than it was in the insulin lispro group, whereas insulin lispro better controlled postprandial blood glucose throughout the day (p<0 .0001). The incidence of hypoglycaemic events was less with insulin glargine than with lispro (5 . 2 [95% CI 1 . 9-8.9] vs 24.0 [21-28] events per patient per year; p<0 .0001). Respective mean weight gains were 3 . 01 (S D 4.33) kg and 3.54 (4.48) kg. The improvement of treatment satisfaction was greater for insulin glargine than for insulin lispro (mean difference 3.13; 95% CI 2.04-4.22). Interpretation A therapeutic regimen involving the addition of either basal or prandial insulin analogue is equally effective in lowering haemoglobin A(1c). We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self monitoring, and greater patient satisfaction than was insulin lispro.
引用
收藏
页码:1073 / 1084
页数:12
相关论文
共 46 条
[1]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[2]  
[Anonymous], 1999, Diabet Med, V16, P716
[3]  
[Anonymous], 1995, Br. Med. J, DOI DOI 10.1136/BMJ.310.6972.83
[4]   Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c [J].
Bastyr, EJ ;
Stuart, CA ;
Brodows, RG ;
Schwartz, S ;
Graf, CJ ;
Zagar, A ;
Robertson, KE .
DIABETES CARE, 2000, 23 (09) :1236-1241
[5]   Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes -: Implications for treatment and monitoring of metabolic control [J].
Bonora, E ;
Calcaterra, F ;
Lombardi, S ;
Bonfante, N ;
Formentini, G ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2001, 24 (12) :2023-2029
[6]   Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes [J].
Boye, Kristina Secnik ;
Matza, Louis S. ;
Oglesby, Alan ;
Malley, Karen ;
Kim, Sunny ;
Hayes, Risa P. ;
Brodows, Robert .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[7]   MEASURES OF PSYCHOLOGICAL WELL-BEING AND TREATMENT SATISFACTION DEVELOPED FROM THE RESPONSES OF PEOPLE WITH TABLET-TREATED DIABETES [J].
BRADLEY, C ;
LEWIS, KS .
DIABETIC MEDICINE, 1990, 7 (05) :445-451
[8]  
Bradley C., 1994, Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice, P111
[9]  
Cefalu WT, 2002, AM J MED, V113, p23S
[10]   Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes [J].
Cryer, PE .
DIABETOLOGIA, 2002, 45 (07) :937-948